We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

N4P N4 Pharma Plc

0.00 (0.00%)
21 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
N4 Pharma Plc LSE:N4P London Ordinary Share GB00BYW8QM32 ORD 0.4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.525 0.45 0.60 0.525 0.525 0.525 10,000 08:00:15
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Drug & Proprietary Stores 2k -1.27M -0.0047 -1.11 1.4M

N4 Pharma PLC Posting of Annual Report & Notice of AGM

29/04/2024 10:59am

RNS Regulatory News

RNS Number : 4170M
N4 Pharma PLC
29 April 2024


N4 Pharma plc

 ("N4 Pharma" or the "Company")


Posting of Annual Report & Notice of AGM


N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces that its Annual Report and Accounts for the year ended 31 December 2023 and Notice of its Annual General Meeting ("AGM") have been posted to shareholders.


The AGM will be held at 11:00am on 23 May 2024 at Shakespeare Martineau LLP, 6th Floor 60 Gracechurch Street, London, EC3V 0HR.


The Group's Annual Report and Accounts and the Notice of AGM are available on the Company's website:



For more information please contact:


N4 Pharma plc

Nigel Theobald, CEO

Luke Cairns, Executive Director


SP Angel Corporate Finance LLP

Nominated Adviser and Joint Broker

Matthew Johnson/Caroline Rowe/Kasia Brzozowska (Corporate Finance)

Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)

Tel: +44(0)20 3470 0470


Engage with us directly at N4 Pharma Investor Hub

Sign up at



About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec®.


N4 Pharma's business model is to partner with companies developing novel antigens in these fields to use Nuvec® as the delivery vehicle for these antigens. As these products progress through pre‐clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.


For further information on the Company visit or sign up at





This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

1 Year N4 Pharma Chart

1 Year N4 Pharma Chart

1 Month N4 Pharma Chart

1 Month N4 Pharma Chart

Your Recent History

Delayed Upgrade Clock